Article citationsMore>>

Layman, R.M., Ruppert, A.S., Lynn, M., Mrozek, E., Ramaswamy, B., Lustberg, M., Wesolowski, R., Ottman, S., Carthers, S., Bingman, A., Reinbolt, R., Kraut, E.H. and Shapiro, C.L. (2013) Severe and Prolonged Lymphopenia Observed in Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer. Cancer Chemotherapy and Pharmacology, 71, 1183-1190.
http://dx.doi.org/10.1007/s00280-013-2112-2

has been cited by the following article:

• TITLE: Novel Approach to Chemotherapy and Administration Selection with Metronomic/Fractionated Dosing

  AUTHORS: Aaron J. Smith, John Oertle, Dino Prato

  KEYWORDS: Metronomic Dosing, Chemotherapy, Multidrug Resistance, Neutropenia, Lymphocytopenia, Insulin, Biomarkers, Cognitive Changes

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.5, May 27, 2015

  ABSTRACT: Metronomic dosing of chemotherapy was introduced in the early 2000s and has since gained recognition as a potential game changer in the manner of which chemotherapy can be administered. There are several known candidates for metronomic dosing of chemotherapy with the potential for many more to be elucidated in the future. Minimized overall side effects, longer durations of treatment, potential minimization of multidrug resistance (MDR) mutations, potential less refractory responses, and the potential to safely use more than one chemotherapy treatments also make metronomic dosing of chemotherapy attractive. Metronomic dosing reduces common side effects and has the potential to reduce neutropenia, lymphocytopenia, and cognitive changes associated with maximum tolerated dosages (MTD). Methods of enhancing chemotherapy including fasting and administration of insulin are also discussed. Metronomic dosing combined with a patient’s molecular profile derived from biomarkers is particularly exciting. It holds significant potential with regard to administrating the most relevant chemotherapies and offers maximal beneficial results.